Brensocatib (Brinsupri) for Bronchiectasis: What You Need to Know
Health ConditionsLung & Respiratory

How Brensocatib (Brinsupri) Treats Bronchiectasis

How Brensocatib (Brinsupri) Treats Bronchiectasis
Insmed
By
Published on March 5, 2026
by

If you’re living with bronchiectasis, you’re likely familiar with the exhausting cycle of thick mucus, chronic coughing, and fear of the next flare-up. For years, treatment has focused on managing symptoms: clearing mucus and fighting infections after they start.

A new treatment has changed the landscape. Since 2025, when the U.S. Food and Drug Administration (FDA) approved the medication brensocatib (Brinsupri), treatment can now target the underlying inflammation that contributes to non-cystic fibrosis bronchiectasis, not just the symptoms.

 Knowing how the drug works and its side effects can help you and your care team find the right treatment for your chronic lung condition.

Brensocatib Targets Inflammation

Brensocatib works by reducing the drivers of the inflammation that damages airways and causes mucus buildup, says Amit “Bobby” Mahajan, MD, a national medical spokesperson for the American Lung Association and the system chief of interventional pulmonology at Inova Health System in Vienna, Virginia.

When bacteria get into your lungs, your body sends out infection-fighting cells called neutrophils. These cells help kill germs and protect you.

But with bronchiectasis, this response can go into overdrive. Neutrophils release powerful enzymes called neutrophil serine proteases to fight infection. Over time, those enzymes can start to harm healthy lung tissue, too.

Brensocatib disrupts that process by blocking an enzyme called DPP1 that helps switch on those damaging enzymes while neutrophils are still developing in your bone marrow. By turning down that activation step, the medication helps limit how much injury neutrophils can cause once they reach the lungs.

This can mean less inflammation, less airway damage, and an easier time clearing mucus, Dr. Mahajan says.

“As a result, people are more functional, are feeling better, and are more active,” he says.

By reducing flare-ups, called exacerbations, brensocatib can also preserve lung function longer term, says Panagis Galiatsatos, MD, a national spokesperson for the American Lung Association and an assistant professor at the Johns Hopkins School of Medicine in Baltimore.

“You want to reduce these exacerbations because they are a burden to a patient,” he says. “[Brensocatib] won't fully reverse the bronchiectasis, but it’ll keep it from being symptomatic.”

The Data

The FDA evaluated positive results from two trials examining how brensocatib can treat bronchiectasis.

In the phase 2 WILLOW study, people taking 10 or 25 milligrams (mg) of brensocatib over 24 weeks reduced their risk of flare-ups by 38 to 42 percent. The medication also helped to extend the time between flare-ups and reduced neutrophil activity.

The larger phase 3 ASPEN trial found a 20 percent reduction in annual flare-ups over 52 weeks for people taking 10 and 25 mg doses. Both doses also extended the time to the first flare-up and increased the likelihood of remaining flare-up-free. People on the 25 mg dose also showed less decline in lung function, measured by forced expiratory volume, the amount of air you can force out in one second.

How to Use Brensocatib

Brensocatib isn’t a replacement for your current bronchiectasis treatment, and you’ll need to continue the daily rituals you already practice to keep your airways clear. The new drug should be used in addition to other treatments, such as postural draining, chest percussion therapy, inhaled therapies, and exercise.

 Brensocatib helps calm inflammation, but it doesn’t clear mucus on its own.

“Depending on the cause of your bronchiectasis, [brensocatib can] be used along with airway clearance and also sometimes still needing pulmonary rehabilitation or surgery,” Mahajan says.

How long you’ll take it depends on your situation. Most people who take brensocatib do so regularly, Mahajan says. Your doctor can work with you on dosage and how long you will need to take it, based on your symptoms and quality-of-life goals.

Because brensocatib works by lowering part of your immune response, a few extra precautions are important while you’re taking it. Talk to your doctor before getting any new vaccines. Your doctor may recommend not getting live attenuated vaccines, such as those for measles or the flu, to avoid interactions.

Dr. Galiatsatos also stresses “appropriate infectious control,” such as wearing a mask during high viral seasons, washing your hands often, and avoiding close contact with people who are sick. These simple steps can help lower your risk of infections that could trigger a flare.

Dosage and Administration

Brensocatib is a once-daily, oral pill, available in 10 and 25 mg doses. You can take it with or without food at any time of the day, but ideally at the same time each day.

Side Effects and Warnings

The most common side effects include:

  • Upper respiratory tract infections
  • Headache
  • Skin issues and rashes
  • Dry or thickening skin, or hyperkeratosis
  • High blood pressure, hypertension
  • Gum or dental problems
Galiatsatos says nausea and gastrointestinal issues are also common, though the newness of the medication means that we might not know all side effects yet. Brensocatib side effects occur more often in people taking the 25 mg dose than in those taking the 10 mg dose.

Less common side effects include:

  • Hair loss (alopecia)
  • Abnormal liver blood tests, indicating potential liver irritation or stress
  • Skin cancer

Galiatsatos also advises people taking brensocatib to have dental checkups every six months because the drug’s effect on tissue enzymes may increase your risk of gum disease.

Live attenuated vaccines also are not recommended while taking brensocatib. Be sure to talk to your doctor about your existing health conditions and vaccine status before starting brensocatib.

The Takeaway

  • Brensocatib (Brinsupri) is the first medication to target the underlying inflammation contributing to bronchiectasis, rather than treating symptoms after they start.
  • Brensocatib can reduce the number of flare-ups of the chronic lung condition and increase the time between them, potentially slowing down the decline of lung function.
  • The medication is available as a daily pill in 10 or 25 mg doses, depending on what your doctor prescribes, and is used in addition to traditional bronchiectasis treatments such as daily airway clearance techniques.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Drug Trials Snapshots: BRINSUPRI. U.S. Food and Drug Administration. November 24, 2025.
  2. Chalmers JD et al. Targeting Neutrophil Serine Proteases in Bronchiectasis. European Respiratory Journal. January 2, 2025.
  3. Chalmers JD et al. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine. April 23, 2025.
  4. Chalmers JD et al. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine. September 7, 2020.
  5. Bronchiectasis. Cleveland Clinic. August 6, 2022.
  6. Babar Z et al. Brensocatib (Brinsupri) First FDA-Approved Targeted Therapy for Non-Cystic Fibrosis Bronchiectasis. Annals of Medicine & Surgery. December 16, 2025.
  7. Brensocatib (Oral Route). Mayo Clinic. February 1, 2026.
  8. Brinsupri. Insmed Inc.2026.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network

Rohan Mankikar, MD

Medical Reviewer

Rohan Mankikar, MD, is the chief of pulmonary medicine at Huntington Hospital and practices on Long Island. Originally from New Jersey, Dr. Mankikar studied medicine at The Medical University of Lublin in Poland. He completed his residency from Morehouse School Of Medicine–Grady Memorial Hospital in Atlanta, and after graduating in 2014, he went on to serve as a chief resident. Thereafter, he completed a fellowship in pulmonary medicine from the University of South Carolina in 2017, where he served as a chief pulmonary fellow.

He was awarded Resident of The Year during residency and was inducted into the Arnold P. Gold Humanism Honor Society for his passion for teaching medical students. He received the Jason B. Spiers Best Teaching Fellow Award from the University of South Carolina.

He has authored several abstracts and research projects in the field of pulmonary–critical care medicine as well as serving on the committee for the Southeast Chapter of the Society of Critical Care Medicine. 

See full bio

Susan Jara

Author

Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging content for diverse audiences of patients and caregivers. She specializes in patient education, health literacy, and SEO-driven content strategy, with expertise across chronic disease, mental health, addiction, arthritis, autoimmune conditions, and wellness.

Susan holds a bachelor’s degree in journalism and media studies from New York University’s Gallatin School of Individualized Study. Her career includes leadership roles at the Global Healthy Living Foundation and Health Monitor Network, where she developed multichannel health content across web, email, podcasts, video, social media, and print. Susan's work reaches millions of readers each year, and she collaborates with leading healthcare providers, researchers, advocacy groups, and industry partners to create resources that reach millions of readers each year.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network